PURPOSE The US Food and Drug Administration has granted regulatory approval for the
use of nivolumab—an immune checkpoint inhibitor (ICI)—in the first-line treatment of …

Background and Aims Patients with T1 colorectal cancer (CRC) are at high risk for lymph
node metastasis and recurrence after local resection (LR) and need surgical resection (SR) …

Importance Immune checkpoint inhibitors (ICIs) have improved survival outcomes of patients
with advanced esophageal squamous cell carcinoma in both first-and second-line settings …

Introduction: Sorafenib was historically the standard of care for advanced hepatocellular
carcinoma (aHCC) until it was superseded by the combination of atezolizumab and …

Methods| We performed a secondary analysis of Keynote 048 using estimated individual
patient data (IPD). Kaplan-Meier curves were graphically reconstructed3 and IPD for …

BACKGROUND Oral SERDs are a novel drug class that have been developed to counteract
resistance due to ESR1 mutations. Several SERDs have emerged from phase 2 and 3 trials …

Abstract Background and Aims The effectiveness of immune checkpoint inhibitors (ICIs) in
low programmed death ligand 1 (PD‐L1) expression in cervical cancer (CC) patients …

To the Editor Liau et al1 report the results of a phase 3 nonrandomized controlled trial of
treatment with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) for …

Introduction: Inhibitors of programmed cell death 1 (PD1) and its ligand (PDL1) have
exhibited favorable long-term survival in many types of advanced-stage cancer and current …

With the recent progress in scientific research, the combination of chemotherapy and PD-1
blockade has become the new standard-of-care first-line treatment for patients with …